Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, observational, real-world, safety and performance evaluation of BioMime Morph Sirolimus Eluting Coronary Stent System for coronary artery lesions - BioMime Morph

Trial Profile

A retrospective, observational, real-world, safety and performance evaluation of BioMime Morph Sirolimus Eluting Coronary Stent System for coronary artery lesions - BioMime Morph

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions
  • Sponsors Meril Life Sciences
  • Most Recent Events

    • 14 Jan 2019 Planned number of patients changed from 64 to 400.
    • 25 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top